Hudson Capital Management LLC Purchases 2,551 Shares of Bristol Myers Squibb Company $BMY

Hudson Capital Management LLC lifted its position in Bristol Myers Squibb Company (NYSE:BMY) by 3.0% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 88,864 shares of the biopharmaceutical company’s stock after acquiring an additional 2,551 shares during the quarter. Hudson Capital Management LLC’s holdings in Bristol Myers Squibb were worth $4,114,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. Community Bank N.A. lifted its holdings in shares of Bristol Myers Squibb by 2.3% in the 2nd quarter. Community Bank N.A. now owns 222,883 shares of the biopharmaceutical company’s stock worth $10,317,000 after acquiring an additional 4,966 shares during the last quarter. Oregon Public Employees Retirement Fund lifted its holdings in shares of Bristol Myers Squibb by 0.9% in the 2nd quarter. Oregon Public Employees Retirement Fund now owns 175,897 shares of the biopharmaceutical company’s stock worth $8,142,000 after acquiring an additional 1,600 shares during the last quarter. Concord Asset Management LLC VA lifted its holdings in shares of Bristol Myers Squibb by 48.4% in the 2nd quarter. Concord Asset Management LLC VA now owns 23,091 shares of the biopharmaceutical company’s stock worth $1,069,000 after acquiring an additional 7,532 shares during the last quarter. Vest Financial LLC lifted its holdings in shares of Bristol Myers Squibb by 39.2% in the 2nd quarter. Vest Financial LLC now owns 23,549 shares of the biopharmaceutical company’s stock worth $1,090,000 after acquiring an additional 6,637 shares during the last quarter. Finally, Pzena Investment Management LLC lifted its holdings in Bristol Myers Squibb by 10.3% during the 2nd quarter. Pzena Investment Management LLC now owns 14,843,475 shares of the biopharmaceutical company’s stock valued at $687,104,000 after buying an additional 1,384,649 shares in the last quarter. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Trading Down 0.9%

NYSE BMY opened at $43.55 on Tuesday. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21. The company has a market capitalization of $88.63 billion, a price-to-earnings ratio of 17.56, a price-to-earnings-growth ratio of 2.26 and a beta of 0.33. The company’s 50-day simple moving average is $46.22 and its two-hundred day simple moving average is $47.84. Bristol Myers Squibb Company has a one year low of $42.96 and a one year high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 EPS for the quarter, beating analysts’ consensus estimates of $1.07 by $0.39. The business had revenue of $12.27 billion for the quarter, compared to the consensus estimate of $11.32 billion. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The company’s revenue for the quarter was up .6% on a year-over-year basis. During the same quarter last year, the firm posted $2.07 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. Equities analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 3rd. Stockholders of record on Friday, October 3rd will be given a $0.62 dividend. The ex-dividend date of this dividend is Friday, October 3rd. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.7%. Bristol Myers Squibb’s payout ratio is presently 100.00%.

Insider Activity

In other news, EVP David V. Elkins sold 56,000 shares of Bristol Myers Squibb stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total value of $2,650,480.00. Following the transaction, the executive vice president owned 167,379 shares of the company’s stock, valued at $7,922,048.07. The trade was a 25.07% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.07% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on BMY shares. Daiwa America lowered shares of Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 5th. Morgan Stanley reiterated a “hold” rating on shares of Bristol Myers Squibb in a report on Thursday, July 31st. Dbs Bank upgraded shares of Bristol Myers Squibb to a “moderate buy” rating in a report on Thursday, October 2nd. Citigroup reiterated a “neutral” rating on shares of Bristol Myers Squibb in a report on Monday. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Bristol Myers Squibb in a report on Saturday, September 27th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and fifteen have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $57.14.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.